5-Oxohexahydrocyclopenta[C]Pyrrole-2-Carboxylic Acid Tert-Butyl Ester

In the industrial preparation of macrocyclic peptide therapeutics requiring a conformationally constrained proline surrogate, 5‑oxohexahydrocyclopenta[c]pyrrole‑2‑carboxylic acid tert‑butyl ester is routinely deployed as a protected bicyclic amino acid scaffold. Production campaigns conducted in ISO 7 cleanrooms under ICH Q7 active pharmaceutical ingredient GMP typically charge 85.0 kg of the ester into a 2500 L glass‑lined reactor equipped with a retreat‑curve impeller and a jacket temperature control system capable of maintaining ±1.5 °C deviation at the set point. The tert‑butyl ester is first removed via exposure to 3.0 M hydrogen chloride in anhydrous dioxane at 18–22 °C under a nitrogen sweep that conveys evolved isobutylene to a thermal oxidizer rated for 99.9 % destruction efficiency; jacket heat removal capacity of 0.35 kW·L⁻¹·min⁻¹ prevents local overheating that would otherwise generate the destructured pyrrolidine ring system as a specified impurity listed under ICH Q3A with a reporting threshold of 0.05 area%. After solvent displacement with dimethylformamide and residual HCl removal until a Karl Fischer end‑point of ≤ 0.02 % w/w water, the free carboxylic acid is coupled in situ with the C‑terminal amine fragment of a macrocyclic NS5A inhibitor. The coupling stoichiometry registers the deprotected acid at 1.08 equivalents versus the amine component in the presence of 1.15 equivalents of HATU and 2.5 equivalents of N,N‑diisopropylethylamine; batch records archive a solution concentration of 0.45 M for the acid and a controlled addition rate of 18 L·h⁻¹ to maintain an internal temperature below 25 °C and keep the activated ester half‑life exceeding 6.0 min. Downstream processing passes the crude diamide through a multi‑plate centrifugal extractor with a pH 5.2 acetate buffer to remove urea by‑products, followed by a silica‑gel‑loaded stainless‑steel column with a bed height‑to‑diameter ratio of 6:1 eluting with 65 : 35 heptane/ethyl acetate; fraction pooling is directed by an online diode‑array UV signal calibrated against a reference standard traceable to USP <857>. The isolated key intermediate crystallizes from methyl tert‑butyl ether with a purity of > 99.4 area% and an enantiomeric excess exceeding 99.8 % by chiral SFC. Terminal finished products sourced from this synthesis stream are rapidly dissolving bilayer tablets containing 50 mg and 100 mg of the NS5A inhibitor, manufactured under 21 CFR 210/211 and submitted to USP <711> dissolution testing.

How does protic solvent coordination shift the diastereomeric ratio during borohydride reduction of the 5‑oxo group to yield an endo‑alcohol precursor for mGluR5 positive allosteric modulators?

A reduction protocol translating the 5‑oxo moiety to an endo‑hydroxy function on a perhydrocyclopenta[c]pyrrole ring system has been qualified in a pilot‑scale facility targeting kilogram supplies of a metabotropic glutamate receptor 5 positive allosteric modulator (mGluR5 PAM). The intermediate, charged at 24.7 kg in a 600 L Hastelloy C‑276 reactor, dissolves at 0.50 M in a tetrahydrofuran/methanol mixture at a 85 : 15 volumetric ratio; the methanol fraction is controlled within ±2 vol% because calorimetry data show that excursions outside this window alter the coordination sphere of the borohydride counter‑ion, shifting the endo/exo product ratio from the target 95 : 5 to as low as 72 : 28. Formulation addition rate applies 1.25 molar equivalents of sodium borohydride as a 12 % w/w slurry in mineral oil, metered through a loss‑in‑weight feeder with an accuracy of ±0.5 %, while the jacket is held at ‑12 ± 1 °C and the internal temperature is monitored by a dual‑channel Pt100 probe linked to a cascade controller that ramps the agitator from 85 rpm to 145 rpm upon detecting a 0.3 °C overshoot. Reaction progress, tracked by in‑line ReactIR with a peak‑height metric at 1708 cm⁻¹, triggers a quench sequence using 2.0 M aqueous ammonium chloride when ketone area normalised to 0.7 % of the initial value, preventing borate ester formation that impedes filtration across a 0.5 m² ceramic membrane. The crude endo‑alcohol is rectified through a wiped‑film evaporator operating at 0.5 mbar and 140 °C jacket temperature before entering a simulated moving‑bed (SMB) chromatography unit with a Chiralpak IG stationary phase and a mobile phase of supercritical CO₂ with 10 % methanol modifier; the SMB unit reaches a productivity of 2.1 kg racemate‑per‑kg‑stationary‑phase‑per‑day and delivers an enantiomeric purity of > 99.9 %. The recovered endo‑alcohol intermediate is spray‑dried using a two‑fluid nozzle at an inlet temperature of 135 °C, producing a powder with D₅₀ = 45 µm that is then telescoped into a Mitsunobu inversion‑free coupling to furnish the mGluR5 PAM free base. Finished oral capsules are formulated at a 30 mg strength with lactose monohydrate direct‑compression excipients and comply with ICH M7 purge factor assessments confirming all potential mutagenic impurities from the borohydride stream remain below 1.5 µg day⁻¹. Regulatory filings reference ICH Q11 for the starting material designation and retain a Type II drug master file with complete history of the hydrogen‑deuterium exchange impurity profile certificated against EP 10.0 Monograph 2024.

A Wittig olefination–hydrogenation tandem sequence has been deployed at multi‑hundred‑kilogram scale to convert the 5‑oxo group into a methylene bridge that constitutes the core conformation of a dipeptidyl peptidase‑4 (DPP‑4) inhibitor. The substrate ester is dissolved at 0.35 M in anhydrous tetrahydrofuran and cooled to ‑22 ± 2 °C inside a 4000 L reactor equipped with a baffled jacket for high‑viscosity slurries; the formulation stoichiometry specifies 1.32 equivalents of methyl triphenylphosphonium bromide pre‑deprotonated with 1.28 equivalents of potassium tert‑butoxide 1.7 M solution in THF, the addition rate limited to 32 L·min⁻¹ to prevent a temperature spike above ‑15 °C that would promote phosphine oxide elimination into triphenylphosphine oxide impurities quantified by ³¹P NMR with a detection limit of 0.05 mol%. After warming to 5 °C over 4.5 h and quenching into ice‑cold ammonium chloride, the organic layer undergoes crossflow filtration across a 0.2 µm ceramic membrane to remove bulk phosphine oxide; the filtrate then directly enters a continuous hydrogenation skid where it is contacted with 5 % palladium‑on‑carbon contained in a fixed‑bed cartridge at 40 °C and 4.5 bar hydrogen pressure, achieving full olefin reduction with a residence time of 14 min. The deprotected pyrrolidine‑carboxylic acid obtained after Boc cleavage is telescoped into a cyanopyrrolidine amide formation identical to the pharmacophore embedded in several approved gliptins; the manufacturing process holds a valid CEP (Certificate of Suitability) under EDQM Resolution AP‑CSP(07)1 and each batch is accompanied by a declaration of compliance with EMEA/CHMP/SWP/4446/2000 for metal residues, with palladium consistently measured at ≤ 6 ppm by ICP‑MS. The downstream finished product is a film‑coated tablet of 25 mg or 100 mg strength, blister‑packed under nitrogen to protect against oxidative degradation triggered by residual peroxide in the polyethylene‑polyvinyl chloride laminate.

Electrophilic Sulfonylation at the Pyrrolidine Nitrogen and Subsequent Boc Deprotection: A Dual‑Functionalization Route to CNS‑Penetrant Carbonic Anhydrase Inhibitors

Manufacturing of a primary sulfonamide‑bearing carbonic anhydrase II inhibitor that requires brain‑partitioning properties begins with chemoselective N‑sulfonylation of the bridgehead amine of 5‑oxohexahydrocyclopenta[c]pyrrole‑2‑carboxylic acid tert‑butyl ester. The transformation is executed in a 1000 L glass‑lined reactor containing the substrate dissolved in dichloromethane at 0.55 M and treated with 1.55 equivalents of 4‑fluorobenzenesulfonyl chloride; 2.05 equivalents of N,N‑diisopropylethylamine are pumped via a peristaltic dosing unit at 8.5 L·h⁻¹ while the jacket circulates chilled glycol at ‑5 °C to hold the internal temperature at 0 ± 2 °C, as calorimetry data indicate that the reaction liberates ‑ΔH = 178 kJ·mol⁻¹ and loses selectivity above 8 °C owing to diaryl sulfonamide formation on the trace enol tautomer of the ketone. The monoadduct is isolated by drowning into 0.5 M aqueous citric acid and extracting with dichloromethane; the crude oil is then treated with 12 % v/v trifluoroacetic acid in dichloromethane at 20–25 °C to remove the tert‑butyl ester, a deprotection that proceeds with a half‑life of 22 min under these conditions as determined by inline ¹⁹F NMR monitoring of the TFA ester intermediate. Following neutralisation and solvent switch to acetonitrile, the free sulfonamide‑carboxylic acid is subjected to a reductive amination with ammonium acetate and sodium triacetoxyborohydride (4.0 equivalents) to install the primary sulfonamide pharmacophore; the solid‑phase scavenging workup uses Isolute SCX‑2 resin cartridges in a flow‑through mode to sequester excess boron residues to < 50 ppm. The active pharmaceutical ingredient crystalizes as a monohydrochloride salt from ethanol/water and is formulated into 50 mg hard gelatin capsules complying with Ph. Eur. 2.9.5 for uniformity of mass. Bioanalytical batch release includes quantification of the dimeric sulfonamide impurity – a process‑related substance that is controlled to ≤ 0.08 % using an ICH Q3B qualification threshold of 0.15 % based on a 200 mg daily dose – and residual palladium from an earlier Suzuki coupling measured against the Ph. Eur. 2.4.20 standard. Process‑scale runs document a yield consistency of 84–88 % over the four‑step sequence and are executed under ICH Q7 with a certified cleanroom classification of ISO 8 during isolation.

If the tert‑Butyl Ester Is Intentionally Retained Until the Final Stage of a Convergent ADC Payload Synthesis

In the assembly of a protease‑cleavable antibody‑drug conjugate (ADC) warhead that employs a constrained bicyclic dipeptide as the cathepsin B recognition sequence, the fully protected ester is preserved through the majority of the synthesis to shield the carboxylic acid from premature activation. The process, conducted inside a ISO 5 isolator located in a Grade C cleanroom, receives the ester at 0.95 kg scale and dissolves it in N‑methyl‑2‑pyrrolidone at 0.62 M for the initial amide coupling with a monomethyl auristatin E (MMAE) intermediate bearing a free N‑terminus; the formulation employs 1.02 equivalents of the pyrrolidine ester, 1.10 equivalents of 1‑[bis(dimethylamino)methylene]‑1H‑1,2,3‑triazolo[4,5‑b]pyridinium 3‑oxid hexafluorophosphate (HATU), and 2.30 equivalents of sym‑collidine, and the reaction is aged at 21 °C for 18 h until the HPLC purity of the coupled product exceeds 98.0 area% with less than 0.50 % residual amine. The crude stream then accepts a dropwise addition of 25 % v/v trifluoroacetic acid in dichloromethane at ‑5 °C to cleave the tert‑butyl ester in the presence of 2.5 % triisopropylsilane as a cation scavenger; this deprotection step is terminated after 90 min when inline FT‑IR indicates the carbonyl stretch of the ester at 1732 cm⁻¹ has decayed to baseline, and the mixture is precipitated directly into cold diethyl ether to yield the free carboxylic acid as a 99.0 % pure solid. The isolated acid is immediately subjected to low‑light conditions and coupled to the self‑immolative para‑aminobenzyl carbamate linker unit through a mixed anhydride method with isobutyl chloroformate and N‑methylmorpholine at ‑20 °C; the resulting linker‑warhead conjugate is purified by preparative reversed‑phase HPLC on a C₁₈ column with a linear gradient of 35–65 % acetonitrile in 0.1 % aqueous acetic acid, collecting the heart‑cut at ≥ 98.5 area% purity. The terminal ADC drug product, a lyophilised powder for injection, is composed of the cysteine‑conjugated monoclonal antibody with a drug‑to‑antibody ratio of 4.0 ± 0.4 and is submitted to Ph. Eur. 2.6.17 for antibody‑dependent cellular cytotoxicity activity and to ICH Q5C for stability studies under refrigerated storage at 5 ± 3 °C. Each batch of the intermediate ester used in the ADC campaign is accompanied by a comprehensive extractables and leachables risk assessment per USP <1663> and a viral safety clearance dossier confirming that the chemical synthesis steps provide a > 12 log₁₀ reduction of model retrovirus, in accordance with ICH Q5A(R2).